Orion Corporation
Finland · FI0009014369 · reports in EUR · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +23% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 39% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 64% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€1.9B
revenue
33%
operating margin
€500M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €1.3B | €1.2B | €1.5B | €1.9B |
| Operating profit | €440M | €275M | €417M | €632M |
| Net profit to shareholders | €350M | €217M | €330M | €500M |
| Earnings per share | €2.49 | €1.54 | €2.35 | €3.56 |
| Dividend per share | n/a | €1.60 | n/a | €1.64 |
| Cash from operations | €434M | €119M | €293M | €317M |
| Capital spending | €57M | €66M | €62M | €73M |
| Cash | €333M | €107M | €206M | €161M |
| Total assets | €1.5B | €1.4B | €1.6B | €2.0B |
| Equity | €908M | €890M | €1.0B | €1.3B |
What they do
In the company's own words, from the annual report.
Orion Corporation and its subsidiaries develop and manufacture human and veterinary pharmaceuticals and active pharmaceutical ingredients that are marketed globally.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.